Which has better earnings and valuation, SURG or STRR?

Star Equity has higher revenue and earnings than SurgePays. Star Equity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $56.96M 0.14 -$36.07M -$1.94 N/A Star Equity $172.16M 0.24 -$5.92M -$2.63 N/A

Is SURG or STRR more profitable?

Star Equity has a net margin of -4.18% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Star Equity's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% Star Equity -4.18% -4.04% -2.40%

Which has better valuation and earnings, NEPH or SURG?

Nephros has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.07 $1.19M $0.07 51.29 SurgePays $56.96M 0.14 -$36.07M -$1.94 N/A

Is NEPH or SURG more profitable?

Nephros has a net margin of 4.06% compared to SurgePays' net margin of -64.91%. Nephros' return on equity of 7.66% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% SurgePays -64.91% N/A -310.16%

Do analysts recommend SURG or NTRB?

SurgePays presently has a consensus price target of $3.50, indicating a potential upside of 970.01%. Given SurgePays' stronger consensus rating and higher possible upside, equities analysts plainly believe SurgePays is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SURG or NTRB more profitable?

SurgePays has a net margin of -64.91% compared to Nutriband's net margin of -448.25%. SurgePays' return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% Nutriband -448.25% -112.64% -97.86%

Which has higher valuation & earnings, TELA or SURG?

SurgePays has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.46 -$38.83M -$0.79 N/A SurgePays $56.96M 0.14 -$36.07M -$1.94 N/A

Is TELA or SURG more profitable?

TELA Bio has a net margin of -49.30% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% SurgePays -64.91% N/A -310.16%

Is NSPR or SURG more profitable?

SurgePays has a net margin of -64.91% compared to InspireMD's net margin of -413.96%. SurgePays' return on equity of 0.00% beat InspireMD's return on equity. Company Net Margins Return on Equity Return on Assets InspireMD -413.96% -69.42% -57.68% SurgePays -64.91% N/A -310.16%

SurgePays (SURG) Competitors

$0.33 -0.01 (-2.27%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$0.32 -0.01 (-1.86%)

As of 08:15 AM Eastern

Compare

SURG vs. STRR, NEPH, NTRB, TELA, and NSPR

Should you buy SurgePays stock or one of its competitors? MarketBeat compares SurgePays with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SurgePays include Star Equity (STRR), Nephros (NEPH), Nutriband (NTRB), TELA Bio (TELA), and InspireMD (NSPR). These companies are all part of the "medical equipment" industry.

How does SurgePays compare to Star Equity?

SurgePays (NASDAQ:SURG) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, SurgePays and SurgePays both had 1 articles in the media. SurgePays' average media sentiment score of 1.87 equaled Star Equity'saverage media sentiment score.

Company	Overall Sentiment
SurgePays	Very Positive
Star Equity	Very Positive

Star Equity has higher revenue and earnings than SurgePays. Star Equity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A
Star Equity	$172.16M	0.24	-$5.92M	-$2.63	N/A

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 3.8% of Star Equity shares are owned by institutional investors. 29.1% of SurgePays shares are owned by company insiders. Comparatively, 31.6% of Star Equity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SurgePays currently has a consensus target price of $3.50, indicating a potential upside of 970.01%. Star Equity has a consensus target price of $28.00, indicating a potential upside of 150.00%. Given SurgePays' higher probable upside, equities research analysts clearly believe SurgePays is more favorable than Star Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Star Equity has a net margin of -4.18% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Star Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Star Equity	-4.18%	-4.04%	-2.40%

SurgePays has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Star Equity has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

Star Equity beats SurgePays on 9 of the 14 factors compared between the two stocks.

How does SurgePays compare to Nephros?

Nephros (NASDAQ:NEPH) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Nephros has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.07	$1.19M	$0.07	51.29
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A

In the previous week, Nephros had 1 more articles in the media than SurgePays. MarketBeat recorded 2 mentions for Nephros and 1 mentions for SurgePays. SurgePays' average media sentiment score of 1.87 beat Nephros' score of 0.47 indicating that SurgePays is being referred to more favorably in the news media.

Company	Overall Sentiment
Nephros	Neutral
SurgePays	Very Positive

41.1% of Nephros shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Comparatively, 29.1% of SurgePays shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nephros has a net margin of 4.06% compared to SurgePays' net margin of -64.91%. Nephros' return on equity of 7.66% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
SurgePays	-64.91%	N/A	-310.16%

Nephros presently has a consensus target price of $6.00, suggesting a potential upside of 67.13%. SurgePays has a consensus target price of $3.50, suggesting a potential upside of 970.01%. Given SurgePays' higher possible upside, analysts plainly believe SurgePays is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Nephros has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

Nephros beats SurgePays on 11 of the 15 factors compared between the two stocks.

How does SurgePays compare to Nutriband?

SurgePays (NASDAQ:SURG) and Nutriband (NASDAQ:NTRB) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

SurgePays presently has a consensus price target of $3.50, indicating a potential upside of 970.01%. Given SurgePays' stronger consensus rating and higher possible upside, equities analysts plainly believe SurgePays is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

SurgePays has a net margin of -64.91% compared to Nutriband's net margin of -448.25%. SurgePays' return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Nutriband	-448.25%	-112.64%	-97.86%

In the previous week, SurgePays and SurgePays both had 1 articles in the media. Nutriband's average media sentiment score of 1.89 beat SurgePays' score of 1.87 indicating that Nutriband is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Very Positive
Nutriband	Very Positive

Nutriband has lower revenue, but higher earnings than SurgePays. Nutriband is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A
Nutriband	$2.04M	17.52	-$8.23M	-$2.58	N/A

SurgePays has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 52.2% of Nutriband shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

SurgePays beats Nutriband on 8 of the 15 factors compared between the two stocks.

How does SurgePays compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

TELA Bio has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

TELA Bio has a net margin of -49.30% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
SurgePays	-64.91%	N/A	-310.16%

In the previous week, TELA Bio and TELA Bio both had 1 articles in the media. TELA Bio's average media sentiment score of 1.89 beat SurgePays' score of 1.87 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
SurgePays	Very Positive

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 5.1% of TELA Bio shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SurgePays has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.46	-$38.83M	-$0.79	N/A
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A

TELA Bio currently has a consensus target price of $2.20, suggesting a potential upside of 169.18%. SurgePays has a consensus target price of $3.50, suggesting a potential upside of 970.01%. Given SurgePays' higher possible upside, analysts clearly believe SurgePays is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

TELA Bio beats SurgePays on 10 of the 15 factors compared between the two stocks.

How does SurgePays compare to InspireMD?

InspireMD (NYSE:NSPR) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 29.1% of SurgePays shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

InspireMD has higher earnings, but lower revenue than SurgePays. InspireMD is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	3.10	-$19.92M	-$0.73	N/A
SurgePays	$56.96M	0.14	-$36.07M	-$1.94	N/A

InspireMD presently has a consensus target price of $4.50, indicating a potential upside of 525.87%. SurgePays has a consensus target price of $3.50, indicating a potential upside of 970.01%. Given SurgePays' higher probable upside, analysts clearly believe SurgePays is more favorable than InspireMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

InspireMD has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, SurgePays has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

In the previous week, SurgePays had 1 more articles in the media than InspireMD. MarketBeat recorded 1 mentions for SurgePays and 0 mentions for InspireMD. SurgePays' average media sentiment score of 1.87 beat InspireMD's score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.

Company	Overall Sentiment
InspireMD	Neutral
SurgePays	Very Positive

SurgePays has a net margin of -64.91% compared to InspireMD's net margin of -413.96%. SurgePays' return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
SurgePays	-64.91%	N/A	-310.16%

Summary

InspireMD beats SurgePays on 9 of the 16 factors compared between the two stocks.

Get SurgePays News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SURG vs. The Competition

Export

Metric	SurgePays	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$8.41M	$18.36B	$39.25B	$12.61B
Dividend Yield	N/A	3.41%	3.19%	8.00%
P/E Ratio	-0.17	68.46	78.52	24.26
Price / Sales	0.14	36.26	597.90	117.88
Price / Cash	N/A	77.06	45.82	49.36
Price / Book	-0.50	6.76	9.49	6.29
Net Income	-$36.07M	$385.08M	$1.07B	$330.66M
7 Day Performance	-20.24%	0.36%	-0.57%	-1.35%
1 Month Performance	-18.20%	6.51%	-1.36%	-0.64%
1 Year Performance	-89.06%	-8.98%	140.11%	19.08%

SurgePays Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SURG SurgePays	4.386 of 5 stars	$0.33 -2.3%	$3.50 +970.0%	-89.6%	$8.41M	$56.96M	N/A	40	Positive News
STRR Star Equity	4.2918 of 5 stars	$11.02 -3.4%	$28.00 +154.2%	+460.0%	$40.76M	$172.16M	N/A	1,200	Positive News
NEPH Nephros	2.0697 of 5 stars	$3.69 +3.8%	$6.00 +62.8%	-0.3%	$40.02M	$18.79M	52.65	30	Gap Up
NTRB Nutriband	0.9805 of 5 stars	$3.17 +0.9%	N/A	-63.1%	$38.54M	$2.04M	N/A	10
TELA TELA Bio	2.9011 of 5 stars	$0.84 +7.2%	$2.20 +161.0%	-59.1%	$37.47M	$80.28M	N/A	120	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SURG) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SurgePays (SURG) Competitors

SURG vs. STRR, NEPH, NTRB, TELA, and NSPR

How does SurgePays compare to Star Equity?

Summary

How does SurgePays compare to Nephros?

Summary

How does SurgePays compare to Nutriband?

Summary

How does SurgePays compare to TELA Bio?

Summary

How does SurgePays compare to InspireMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SurgePays (SURG) Competitors

SURG vs. STRR, NEPH, NTRB, TELA, and NSPR

How does SurgePays compare to Star Equity?

Does the media prefer SURG or STRR?

Which has better earnings and valuation, SURG or STRR?

Do institutionals & insiders believe in SURG or STRR?

Do analysts rate SURG or STRR?

Is SURG or STRR more profitable?

Which has more risk and volatility, SURG or STRR?

Summary

How does SurgePays compare to Nephros?

Which has better valuation and earnings, NEPH or SURG?

Does the media refer more to NEPH or SURG?

Do insiders and institutionals believe in NEPH or SURG?

Is NEPH or SURG more profitable?

Do analysts rate NEPH or SURG?

Which has more volatility & risk, NEPH or SURG?

Summary

How does SurgePays compare to Nutriband?

Do analysts recommend SURG or NTRB?

Is SURG or NTRB more profitable?

Does the media prefer SURG or NTRB?

Which has higher earnings and valuation, SURG or NTRB?

Which has more volatility and risk, SURG or NTRB?

Do institutionals and insiders have more ownership in SURG or NTRB?

Summary

How does SurgePays compare to TELA Bio?

Which has more volatility and risk, TELA or SURG?

Is TELA or SURG more profitable?

Does the media favor TELA or SURG?

Do institutionals & insiders hold more shares of TELA or SURG?

Which has higher valuation & earnings, TELA or SURG?

Do analysts prefer TELA or SURG?

Summary

How does SurgePays compare to InspireMD?

Do insiders & institutionals have more ownership in NSPR or SURG?

Which has higher valuation and earnings, NSPR or SURG?

Do analysts rate NSPR or SURG?

Which has more risk & volatility, NSPR or SURG?

Does the media favor NSPR or SURG?

Is NSPR or SURG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SURG vs. The Competition

SurgePays Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools